Clinical Evidence for Tirzepatide in Heart Risk Reduction
Comments Off on Clinical Evidence for Tirzepatide in Heart Risk Reduction
May 10, 2026
Tirzepatide cardiovascular mortality reduction is supported by clinical evidence demonstrating a 62% decrease in death risk among post-PCI patients. This dual incretin receptor agonist offers cardioprotective benefits beyond glucose control. These…
Young Man’s Heart Attack Linked to Cannabis Use — But One Case Can’t Prove Causation
Comments Off on Young Man’s Heart Attack Linked to Cannabis Use — But One Case Can’t Prove Causation
April 16, 2026
This cannabis-induced Wellens syndrome case report details a young man's heart attack linked to cannabis use. The report highlights the complexity of attributing causation due to tobacco co-use and other risk factors. It underscores the need for further…